SI1853631T1 - Fuzijski konstrukti, ki zajemajo regijo FC in se vežejo na fosfatidilserine, ter njihova terapevtska uporaba - Google Patents
Fuzijski konstrukti, ki zajemajo regijo FC in se vežejo na fosfatidilserine, ter njihova terapevtska uporabaInfo
- Publication number
- SI1853631T1 SI1853631T1 SI200632035T SI200632035T SI1853631T1 SI 1853631 T1 SI1853631 T1 SI 1853631T1 SI 200632035 T SI200632035 T SI 200632035T SI 200632035 T SI200632035 T SI 200632035T SI 1853631 T1 SI1853631 T1 SI 1853631T1
- Authority
- SI
- Slovenia
- Prior art keywords
- phosphatidylserine
- therapeutic use
- fusion constructs
- constructs binding
- binding
- Prior art date
Links
- TZCPCKNHXULUIY-RGULYWFUSA-N 1,2-distearoyl-sn-glycero-3-phosphoserine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@H](N)C(O)=O)OC(=O)CCCCCCCCCCCCCCCCC TZCPCKNHXULUIY-RGULYWFUSA-N 0.000 title 1
- ZWZWYGMENQVNFU-UHFFFAOYSA-N Glycerophosphorylserin Natural products OC(=O)C(N)COP(O)(=O)OCC(O)CO ZWZWYGMENQVNFU-UHFFFAOYSA-N 0.000 title 1
- 230000004927 fusion Effects 0.000 title 1
- 230000001225 therapeutic effect Effects 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/775—Apolipopeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
- A61K47/6817—Toxins
- A61K47/6831—Fungal toxins, e.g. alpha sarcine, mitogillin, zinniol or restrictocin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6891—Pre-targeting systems involving an antibody for targeting specific cells
- A61K47/6897—Pre-targeting systems with two or three steps using antibody conjugates; Ligand-antiligand therapies
- A61K47/6898—Pre-targeting systems with two or three steps using antibody conjugates; Ligand-antiligand therapies using avidin- or biotin-conjugated antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/0002—General or multifunctional contrast agents, e.g. chelated agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/06—Antibacterial agents for tuberculosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3076—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/44—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/77—Internalization into the cell
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Virology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Genetics & Genomics (AREA)
- Toxicology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Nanotechnology (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- Ophthalmology & Optometry (AREA)
- Marine Sciences & Fisheries (AREA)
- Medical Informatics (AREA)
- Crystallography & Structural Chemistry (AREA)
- General Engineering & Computer Science (AREA)
- Cardiology (AREA)
- Rheumatology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US64633305P | 2005-01-24 | 2005-01-24 | |
EP06719706.1A EP1853631B1 (en) | 2005-01-24 | 2006-01-24 | Fc FUSION CONSTRUCTS BINDING TO PHOSPHATIDYLSERINE AND THEIR THERAPEUTIC USE |
PCT/US2006/002964 WO2006079120A2 (en) | 2005-01-24 | 2006-01-24 | Fc-fusion constructs binding to phosphatidylserine and their therapeutic use |
Publications (1)
Publication Number | Publication Date |
---|---|
SI1853631T1 true SI1853631T1 (sl) | 2016-04-29 |
Family
ID=36693034
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SI200632035T SI1853631T1 (sl) | 2005-01-24 | 2006-01-24 | Fuzijski konstrukti, ki zajemajo regijo FC in se vežejo na fosfatidilserine, ter njihova terapevtska uporaba |
Country Status (14)
Country | Link |
---|---|
US (3) | US8956616B2 (sl) |
EP (1) | EP1853631B1 (sl) |
JP (2) | JP5127043B2 (sl) |
CN (3) | CN101146826A (sl) |
AU (1) | AU2006206187B2 (sl) |
CA (1) | CA2591914C (sl) |
DK (1) | DK1853631T3 (sl) |
ES (1) | ES2565543T3 (sl) |
HK (2) | HK1198255A1 (sl) |
IL (1) | IL184406A (sl) |
NZ (1) | NZ556065A (sl) |
SG (1) | SG158919A1 (sl) |
SI (1) | SI1853631T1 (sl) |
WO (1) | WO2006079120A2 (sl) |
Families Citing this family (66)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20050222030A1 (en) * | 2001-02-21 | 2005-10-06 | Anthony Allison | Modified annexin proteins and methods for preventing thrombosis |
US20090291086A1 (en) * | 2001-02-21 | 2009-11-26 | Alavita Pharmaceuticals, Inc. | Compositions and Methods for Treating Cerebral Thrombosis and Global Cerebral Ischemia |
GB0707034D0 (en) * | 2007-04-12 | 2007-05-23 | St Andrews The | Compounds |
US20110064744A1 (en) * | 2007-05-30 | 2011-03-17 | Sabbadini Roger A | Prevention and treatment of pain using antibodies to lysophosphatidic acid |
US9163091B2 (en) * | 2007-05-30 | 2015-10-20 | Lpath, Inc. | Compositions and methods for binding lysophosphatidic acid |
US8158124B2 (en) * | 2007-05-30 | 2012-04-17 | Lpath, Inc. | Compositions and methods for binding lysophosphatidic acid |
EP2209420A4 (en) | 2007-10-09 | 2014-01-22 | Univ St Louis | IMAGING PARTICLES |
US9468607B2 (en) | 2007-10-09 | 2016-10-18 | Washington University | Ligand directed toroidal nanoparticles for therapy and diagnostic imaging |
WO2009065065A1 (en) * | 2007-11-15 | 2009-05-22 | Ceramoptec Industries, Inc. | Pegylated liposomal formulations for photodynamic treatment of inflammatory diseases |
GB0723797D0 (en) | 2007-12-05 | 2008-01-16 | Immunosolv Ltd | Method |
WO2009089098A1 (en) * | 2008-01-03 | 2009-07-16 | Musc Foundation For Research Development | Methods for the treatment of cancers |
CN102046151A (zh) * | 2008-03-26 | 2011-05-04 | 牛津大学 | 靶向内质网的脂质体 |
GB0819287D0 (en) | 2008-10-22 | 2008-11-26 | Univ Bradford | Compounds |
NZ593281A (en) | 2008-12-05 | 2012-12-21 | Abraxis Bioscience Llc | Sparc binding peptides and uses thereof |
WO2011036467A1 (en) * | 2009-09-24 | 2011-03-31 | Russell David Keenan | Products useful in the treatment of haemophilia |
WO2011069090A1 (en) * | 2009-12-04 | 2011-06-09 | Alavita Pharmaceuticals, Inc. | Inhibition of the activation of coagulation factor xii by ligands of phosphatidylserine |
EP2512452B1 (en) | 2009-12-17 | 2018-09-19 | The Washington University | Antithrombotic nanoparticle |
US9808500B2 (en) | 2009-12-17 | 2017-11-07 | Washington University | Antithrombotic nanoparticle |
EP2369551B1 (en) * | 2010-03-25 | 2019-10-30 | Emory University | Imaging system and method |
CA2796435C (en) * | 2010-04-15 | 2019-05-07 | The Washington University | Prodrug compositions, prodrug nanoparticles, and methods of use thereof |
CN105524176B (zh) * | 2010-05-21 | 2021-03-19 | 银溪制药股份有限公司 | 双特异性融合蛋白 |
EP2571992B1 (en) | 2010-05-21 | 2018-04-25 | Merrimack Pharmaceuticals, Inc. | Bi-specific fusion proteins |
WO2012030949A2 (en) * | 2010-09-01 | 2012-03-08 | Kansas State University Research Foundation | B2-glycoprotein i peptide inhibitors |
US9901616B2 (en) | 2011-08-31 | 2018-02-27 | University Of Georgia Research Foundation, Inc. | Apoptosis-targeting nanoparticles |
US9463217B1 (en) * | 2012-02-10 | 2016-10-11 | Institut National De La Santé Et De La Recherche Médicale (Inserm) | Methods and pharmaceutical compositions for treatment of retinal occlusion |
WO2013123298A1 (en) | 2012-02-17 | 2013-08-22 | University Of Georgia Research Foundation, Inc. | Nanoparticles for mitochondrial trafficking of agents |
CA2879542A1 (en) * | 2012-07-25 | 2014-01-30 | Salk Institute For Biological Studies | Regulating the interaction between tam ligands and lipid membranes with exposed phosphatidylserine |
US20140287024A1 (en) * | 2013-03-08 | 2014-09-25 | Shu Wang | Nanoparticle-based delivery system with oxidized phospholipids as targeting ligands for the prevention, diagnosis and treatment of atherosclerosis |
EP3524617B1 (en) * | 2013-03-15 | 2023-04-12 | GLAdiator Biosciences, Inc. | Gla domains as therapeutic agents |
GB2516882A (en) | 2013-08-02 | 2015-02-11 | Univ Bradford | Tumour-targeted theranostic |
AU2014365838B2 (en) | 2013-12-16 | 2021-01-14 | The University Of North Carolina At Chapel Hill | Depletion of plasmacytoid dendritic cells |
US10398663B2 (en) | 2014-03-14 | 2019-09-03 | University Of Georgia Research Foundation, Inc. | Mitochondrial delivery of 3-bromopyruvate |
CN106536056B (zh) | 2014-06-13 | 2021-07-16 | 儿童医学中心公司 | 分离线粒体的产品和方法 |
US11000603B2 (en) | 2015-04-14 | 2021-05-11 | Benhealth Biopharmaceutic (Shenzhen) Co., Ltd. | Multi-specific binding conjugate, related pharmaceutical compositions and use |
ES2912989T3 (es) * | 2015-05-05 | 2022-05-30 | Rubicon Biotechnology Llc | Inmunoterapia para cáncer |
AU2016276750A1 (en) | 2015-06-09 | 2018-01-18 | The Board Of Regents Of The University Of Texas System | Diagnostic test for early stage cancer |
US10040840B2 (en) * | 2015-10-02 | 2018-08-07 | Silver Creek Pharmaceuticals, Inc. | Bi-specific annexin A5/IGF-1 proteins and methods of use thereof to promote regeneration and survival of tissue |
CN108430499B (zh) | 2015-12-15 | 2022-07-19 | 肿瘤免疫股份有限公司 | 嵌合和人源化抗人类ctla4单克隆抗体和其用途 |
EP3735976A3 (en) * | 2016-01-15 | 2021-01-27 | The Children's Medical Center Corporation | Therapeutic use of mitochondria and combined mitochondrial agents |
WO2017133018A1 (zh) * | 2016-02-06 | 2017-08-10 | 法玛科技顾问股份有限公司 | 重组β2-糖蛋白胜肽及其于抗肿瘤的应用 |
CN109195992A (zh) * | 2016-04-29 | 2019-01-11 | 本康生物制药(深圳)有限公司 | 多特异性结合偶联物、相关的药物组合物及应用 |
WO2017219974A1 (zh) | 2016-06-22 | 2017-12-28 | 本康生物制药(深圳)有限公司 | 用于肿瘤治疗的双特异性抗体和抗体偶联物及其应用 |
EA038617B1 (ru) * | 2016-07-06 | 2021-09-23 | Онкоиммьюн, Инк. | Химерные и гуманизированные античеловеческие ctla-4 моноклональные антитела и их использование |
ES2912269T3 (es) | 2016-09-27 | 2022-05-25 | Cero Therapeutics Inc | Moléculas de receptor de engullimiento quimérico |
MX2019003569A (es) | 2016-09-27 | 2020-07-22 | Oncologie Inc | Metodos para tratar el cancer con bavituximab en funcion de niveles de b2 glucoproteina 1 y ensayos de estos. |
KR20200020662A (ko) | 2017-04-03 | 2020-02-26 | 온콜로지, 인크. | 면역-종양학 제제와 함께 ps-표적화 항체를 사용하여 암을 치료하는 방법 |
CN108727489B (zh) * | 2017-04-19 | 2021-02-09 | 广州市第八人民医院 | 一种单克隆抗体zk2c2及应用 |
WO2019023156A1 (en) * | 2017-07-24 | 2019-01-31 | Rutgers, The State University Of New Jersey | PHOSPHATIDYLSERIN-TARGETING FUSION MOLECULES AND METHODS OF USE |
US11661447B2 (en) | 2017-08-03 | 2023-05-30 | The Cleveland Clinic Foundation | Human β2-glycoprotein I expression |
JP7365704B2 (ja) * | 2017-09-05 | 2023-10-20 | グラディエーター バイオサイエンシーズ インコーポレイテッド | 幹細胞へのペイロードの送達 |
US11708423B2 (en) | 2017-09-26 | 2023-07-25 | Cero Therapeutics, Inc. | Chimeric engulfment receptor molecules and methods of use |
CN108021784B (zh) * | 2017-12-01 | 2021-05-11 | 大连理工大学 | 纳米金属氧化物光致产生活性氧物种的预测方法 |
ES2727261B2 (es) * | 2018-04-12 | 2020-05-06 | Fundacion Para La Investig Biomedica Del Hospital 12 De Octubre | INMUNOCOMPLEJOS ARTIFICIALES Y SU USO COMO CALIBRES EN SISTEMAS DE DETECCION DE INMUNOCOMPLEJOS CIRCULANTES B2GP1-aB2GP1 |
WO2020097165A1 (en) * | 2018-11-08 | 2020-05-14 | Nasr Mahmoud | Nanodiscs for preventing and treating pathogen infections and methods of use thereof |
TW202039583A (zh) | 2018-12-07 | 2020-11-01 | 瑞士商巴克斯歐塔有限公司 | 結合因子IXa及因子X的蛋白分子 |
WO2020114614A1 (en) | 2018-12-07 | 2020-06-11 | Baxalta GmbH | Proteinaceous molecules binding factor ixa and factor x |
EP3711772A1 (en) * | 2019-03-20 | 2020-09-23 | Oslo Universitetssykehus HF | Recombinant proteins and fusion proteins |
WO2020264181A1 (en) * | 2019-06-28 | 2020-12-30 | The Board Of Regents Of The University Of Oklahoma | Therapeutic annexin-drug conjugates and methods of use |
US20220033426A1 (en) * | 2020-07-28 | 2022-02-03 | Yale University | Transition Metal Macrocyclics as MRI Contrast Agents for Molecular Imaging |
EP4188361A1 (en) * | 2020-08-21 | 2023-06-07 | The University of Chicago | Nanoparticles containing multiple cleavable produgs for cancer therapy |
JP2024512207A (ja) * | 2021-02-05 | 2024-03-19 | ヴィクィ インク. | 細胞の形態学的変化の早期検出のための機械学習 |
CN114002133B (zh) * | 2021-10-25 | 2023-01-24 | 南京大学 | 血清中ps阳性外泌体作为乳腺癌化疗敏感性标志物的应用 |
WO2023141524A2 (en) * | 2022-01-19 | 2023-07-27 | Lyndra Therapeutics, Inc. | Dosage forms for gastric retention |
CN114288399B (zh) * | 2022-01-20 | 2023-10-27 | 武汉科技大学 | 一种嵌合抗原受体联合抗肿瘤药物组合物及其应用 |
US20230324382A1 (en) * | 2022-02-01 | 2023-10-12 | Trustees Of Tufts College | Antiphospholipid antibodies for the diagnosis of lyme disease |
WO2023150672A1 (en) * | 2022-02-04 | 2023-08-10 | Duke University | Compositions for and methods of treating hematological cancers |
Family Cites Families (53)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5245015A (en) * | 1991-04-26 | 1993-09-14 | Tanox Biosystems, Inc. | Monoclonal antibodies which neutralize HIV-1 through reaction with a conformational epitope in vitro |
CA2058769C (en) * | 1990-04-06 | 1999-03-02 | Steven Anthony Krilis | Methods for determining phospholipids and antibodies thereof |
ATE175275T1 (de) * | 1992-02-05 | 1999-01-15 | Yamasa Corp | Festphasenreagenz und selbiges verwendendes antikörpertestverfahren |
WO1994013323A1 (en) | 1992-12-04 | 1994-06-23 | The Liposome Company, Inc. | Method of inhibiting the clearance of liposomes from the circulation |
FR2701319B1 (fr) * | 1993-02-09 | 1995-04-21 | Elie Stefas | Procédé de détection et/ou de dosage de composés viraux et support portant une glycoprotéine. |
FR2701263B1 (fr) * | 1993-02-09 | 1995-04-21 | Elie Stefas | Procédé d'obtention d'une composition aqueuse protéinique, composition correspondante, glycoprotéine contenue et son utilisation pour la stabilisation de l'albumine et la détection ou le dosage d'anticorps. |
US5900359A (en) * | 1993-09-29 | 1999-05-04 | Yamasa Corporation | Method for determination of oxidized lipoproteins and use thereof |
CA2176007A1 (en) * | 1993-11-16 | 1995-05-26 | Eiji Matsuura | Method of assaying antiphospholipid antibody and kit therefor |
WO1996004559A1 (fr) * | 1994-08-01 | 1996-02-15 | Institut Français De Recherches Scientifiques Pour Le Developpement En Cooperation - Orstom | Procede de separation et/ou de detection et/ou de quantification de compose(s) infectieux et support pour la mise en ×uvre du procede |
FR2722991B1 (fr) | 1994-08-01 | 1996-10-11 | Orstom | Utilisation de la beta2-glycoproteine i sous au moins une de ses formes comme agent anti-infectueux et composition pharmaceutique corrrespondante |
US5817789A (en) * | 1995-06-06 | 1998-10-06 | Transkaryotic Therapies, Inc. | Chimeric proteins for use in transport of a selected substance into cells |
US5874409A (en) * | 1995-06-07 | 1999-02-23 | La Jolla Pharmaceutical Company | APL immunoreactive peptides, conjugates thereof and methods of treatment for APL antibody-mediated pathologies |
US6203980B1 (en) * | 1998-02-02 | 2001-03-20 | University Of Pittsburgh | Identification of apolipoprotein H mutations and their diagnostic uses |
US6858210B1 (en) * | 1998-06-09 | 2005-02-22 | La Jolla Pharmaceutical Co. | Therapeutic and diagnostic domain 1 β2GPI polypeptides and methods of using same |
IL125262A0 (en) * | 1998-07-07 | 1999-03-12 | Yeda Res & Dev | Synthetic peptides and pharmaceutical compositions comprising them |
JP2000028607A (ja) | 1998-07-10 | 2000-01-28 | Iatron Lab Inc | 新規なモノクローナル抗体及びニックβ2グリコプロテインIの免疫学的分析方法 |
ES2233065T3 (es) * | 1998-07-13 | 2005-06-01 | Board Of Regents, The University Of Texas System | Utilizacion de anticuerpos anti-aminofosfolipidos para el tratamiento del cancer. |
US6818213B1 (en) * | 1998-07-13 | 2004-11-16 | Board Of Regents, The University Of Texas System | Cancer treatment compositions comprising therapeutic conjugates that bind to aminophospholipids |
US6406693B1 (en) * | 1998-07-13 | 2002-06-18 | Board Of Regents, The University Of Texas System | Cancer treatment methods using antibodies to aminophospholipids |
CA2331789C (en) * | 1998-07-13 | 2013-09-10 | Board Of Regents, The University Of Texas System | Cancer treatment methods using therapeutic conjugates that bind to aminophospholipids |
US20050197283A1 (en) * | 1998-10-04 | 2005-09-08 | Vascular Biogenics Ltd. | Compositions containing beta 2-glycoprotein I for the prevention and/or treatment of vascular disease |
IL126447A (en) * | 1998-10-04 | 2004-09-27 | Vascular Biogenics Ltd | An immune preparation that confers tolerance in oral administration and its use in the prevention and / or treatment of atherosclerosis |
US20050148499A1 (en) * | 1998-10-04 | 2005-07-07 | Dror Harats | Compositions containing beta 2-glycoprotein I for the prevention and/or treatment of atherosclerosis |
AUPQ272699A0 (en) | 1999-09-09 | 1999-09-30 | Unisearch Limited | Use of beta2GPI in diagnostic tests for autoimmune diseases |
US7600039B2 (en) * | 2000-02-16 | 2009-10-06 | Motorola, Inc. | Label-based multiplexing |
CA2402211A1 (en) | 2000-03-08 | 2001-09-13 | National Jewish Medical And Research Center | Phosphatidyl serine receptors and uses thereof |
EP1292337A2 (en) * | 2000-06-08 | 2003-03-19 | La Jolla Pharmaceutical | Multivalent platform molecules comprising high molecular weight polyethylene oxide |
JP4336498B2 (ja) * | 2000-12-12 | 2009-09-30 | メディミューン,エルエルシー | 延長した半減期を有する分子ならびにその組成物および用途 |
US20020127698A1 (en) * | 2001-01-26 | 2002-09-12 | Ralf Geiben Lynn | Serpin drugs for treatment of HIV infection and method of use thereof |
WO2002100445A1 (en) | 2001-06-13 | 2002-12-19 | The University Of Sydney | Treatment and composition for wound healing |
FR2827047B1 (fr) * | 2001-07-03 | 2003-09-26 | Apoh Technollgies Sa | Procede de separation et/ou detection et/ou identification et/ou quantification de proteines prions |
JP4681175B2 (ja) | 2001-09-28 | 2011-05-11 | 三菱化学メディエンス株式会社 | 播種性血管内凝固症候群及びその発症前段階を検出する方法 |
JP4070443B2 (ja) * | 2001-10-11 | 2008-04-02 | 株式会社三菱化学ヤトロン | 脳梗塞を検出する方法 |
US20030100036A1 (en) * | 2001-11-08 | 2003-05-29 | Aristo Vojdani | Saliva immunoassay for detection of antibodies for cardiovascular disease |
AU2002361642A1 (en) * | 2001-11-16 | 2003-06-10 | The University Of Tennessee Research Corporation | Recombinant antibody fusion proteins and methods for detection of apoptotic cells |
US7329642B2 (en) * | 2002-05-17 | 2008-02-12 | Board Of Regents, University Of Texas System | β-2-glycoprotein is an inhibitor of angiogenesis |
US7906115B2 (en) * | 2002-07-15 | 2011-03-15 | Thorpe Philip E | Combinations kits and methods for treating viral infections using antibodies and immunoconjugates to aminophospholipids |
US7247303B2 (en) * | 2002-07-15 | 2007-07-24 | Board Of Regents, The University Of Texas System | Selected antibody CDRs for binding to aminophospholipids |
US7615223B2 (en) * | 2002-07-15 | 2009-11-10 | Board Of Regents, The University Of Texas System | Selected immunoconjugates for binding to aminophospholipids |
US7611704B2 (en) * | 2002-07-15 | 2009-11-03 | Board Of Regents, The University Of Texas System | Compositions and methods for treating viral infections using antibodies and immunoconjugates to aminophospholipids |
US7455833B2 (en) * | 2002-07-15 | 2008-11-25 | Board Of Regents, The University Of Texas System | Methods and compositions for treating viral infections using antibodies and immunoconjugates to aminophospholipids |
US7625563B2 (en) * | 2002-07-15 | 2009-12-01 | Board Of Regents, The University Of Texas System | Cancer treatment methods using selected immunoconjugates for binding to aminophospholipids |
US7790159B2 (en) * | 2002-07-15 | 2010-09-07 | Board Of Regents, The University Of Texas System | Methods, combinations and kits for treating viral infections using immunoconjugates and antibodies to aminophospholipids |
US7714109B2 (en) * | 2002-07-15 | 2010-05-11 | Board Of Regents, The University Of Texas System | Combinations and kits for cancer treatment using selected antibodies to aminophospholipids |
US7572448B2 (en) * | 2002-07-15 | 2009-08-11 | Board Of Regents, The University Of Texas System | Combined cancer treatment methods using selected antibodies to aminophospholipids |
US7622118B2 (en) * | 2002-07-15 | 2009-11-24 | Board Of Regents, The University Of Texas System | Cancer treatment methods using selected antibodies to aminophospholipids |
DK2283868T3 (en) * | 2002-07-15 | 2016-04-25 | Univ Texas | PEPTIDES BINDING TO PHOSPHATIDYLETHANOLAMINE AND ITS USE IN TREATING VIRUS INFECTIONS AND CANCER |
US7678386B2 (en) * | 2002-07-15 | 2010-03-16 | Board Of Regents The University Of Texas | Liposomes coated with selected antibodies that bind to aminophospholipids |
ATE512364T1 (de) * | 2002-08-07 | 2011-06-15 | Ablynx Nv | Modulation der blutplättchen-adhäsion basierend auf dem oberflächen-exponierten beta-switch loop des blutplättchen-glycoproteins ib-alpha |
AU2004239244C1 (en) | 2003-05-06 | 2015-04-23 | Bioverativ Therapeutics Inc. | Clotting factor-Fc chimeric proteins to treat hemophilia |
US8198020B2 (en) * | 2003-08-22 | 2012-06-12 | Potentia Pharmaceuticals, Inc. | Compositions and methods for enhancing phagocytosis or phagocyte activity |
US20090068207A1 (en) | 2005-04-15 | 2009-03-12 | Vascular Biogenics Ltd. | Compositions Containing Beta 2-Glycoprotein I-Derived Peptides for the Prevention and/or Treatment of Vascular Disease |
EP1872132B1 (en) * | 2005-04-18 | 2013-09-18 | Bio-Rad Laboratories, Inc. | Solid phase immobilization of phospholipids and cofactor proteins via covalent attachment |
-
2006
- 2006-01-24 CN CNA2006800070648A patent/CN101146826A/zh active Pending
- 2006-01-24 WO PCT/US2006/002964 patent/WO2006079120A2/en active Application Filing
- 2006-01-24 SG SG201000541-1A patent/SG158919A1/en unknown
- 2006-01-24 CN CN201410333397.6A patent/CN104277117A/zh not_active Withdrawn
- 2006-01-24 NZ NZ556065A patent/NZ556065A/en unknown
- 2006-01-24 CN CN201410301233.5A patent/CN104109209B/zh not_active Expired - Fee Related
- 2006-01-24 SI SI200632035T patent/SI1853631T1/sl unknown
- 2006-01-24 DK DK06719706.1T patent/DK1853631T3/en active
- 2006-01-24 EP EP06719706.1A patent/EP1853631B1/en not_active Not-in-force
- 2006-01-24 US US11/339,392 patent/US8956616B2/en active Active
- 2006-01-24 JP JP2007552418A patent/JP5127043B2/ja not_active Expired - Fee Related
- 2006-01-24 AU AU2006206187A patent/AU2006206187B2/en not_active Ceased
- 2006-01-24 ES ES06719706.1T patent/ES2565543T3/es active Active
- 2006-01-24 CA CA2591914A patent/CA2591914C/en not_active Expired - Fee Related
-
2007
- 2007-07-04 IL IL184406A patent/IL184406A/en not_active IP Right Cessation
-
2012
- 2012-03-14 JP JP2012057880A patent/JP2012111783A/ja not_active Withdrawn
-
2014
- 2014-11-21 HK HK14111797.6A patent/HK1198255A1/zh not_active IP Right Cessation
-
2015
- 2015-02-02 US US14/611,634 patent/US20160015826A1/en not_active Abandoned
- 2015-06-05 HK HK15105389.1A patent/HK1205133A1/xx unknown
-
2016
- 2016-07-12 US US15/207,955 patent/US20160311886A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
CN104277117A (zh) | 2015-01-14 |
CN104109209A (zh) | 2014-10-22 |
CN104109209B (zh) | 2016-06-08 |
EP1853631B1 (en) | 2016-03-09 |
DK1853631T3 (en) | 2016-03-29 |
AU2006206187B2 (en) | 2011-03-10 |
US20060228299A1 (en) | 2006-10-12 |
ES2565543T3 (es) | 2016-04-05 |
JP5127043B2 (ja) | 2013-01-23 |
CA2591914A1 (en) | 2006-07-27 |
EP1853631A2 (en) | 2007-11-14 |
IL184406A (en) | 2014-11-30 |
WO2006079120A3 (en) | 2007-07-19 |
SG158919A1 (en) | 2010-02-26 |
HK1205133A1 (en) | 2015-12-11 |
JP2008528521A (ja) | 2008-07-31 |
JP2012111783A (ja) | 2012-06-14 |
US8956616B2 (en) | 2015-02-17 |
US20160311886A1 (en) | 2016-10-27 |
CA2591914C (en) | 2017-04-25 |
US20160015826A1 (en) | 2016-01-21 |
CN101146826A (zh) | 2008-03-19 |
AU2006206187A1 (en) | 2006-07-27 |
WO2006079120A2 (en) | 2006-07-27 |
NZ556065A (en) | 2009-04-30 |
IL184406A0 (en) | 2008-12-29 |
HK1198255A1 (zh) | 2015-03-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SI1853631T1 (sl) | Fuzijski konstrukti, ki zajemajo regijo FC in se vežejo na fosfatidilserine, ter njihova terapevtska uporaba | |
PL1877090T3 (pl) | Trimeryczne białko fuzyjne OX-40-immunoglobulina i sposoby zastosowania | |
ZA201002644B (en) | Axmi-066 and axmi-076:delta-endotoxin proteins and methods for their use | |
EP2007884A4 (en) | ENZYMATIC FUSION PROTEINS AND THEIR USE | |
IL195675A0 (en) | Human binding molecules having killing activity against staphylococci and uses thereof | |
ZA200702222B (en) | Modified Fc molecules | |
HRP20140271T1 (hr) | Humana antitijela protiv bjesnoä†e i njihova uporaba | |
IL187090A0 (en) | ANTIGEN BINDING MOLECULES HAVING MODIFIED Fc REGIONS AND ALTERED BINDING TO Fc RECEPTORS | |
PL2532679T3 (pl) | Ludzkie przeciwciała przeciwko IL13 i zastosowania terapeutyczne | |
IL200808A0 (en) | Soluble il-17ra/rc fusion proteins and related methods | |
EP1877437A4 (en) | CHIMERIC PROTEINS HAVING PHOSPHATIDYLSERIN BINDING DOMAINS | |
ZA200809394B (en) | Rage fusion proteins, formulations, and methods of use thereof | |
EP2198301A4 (en) | PEPTIDE LIPID CONSTRUCTS AND THEIR USE IN DIAGNOSTIC AND THERAPEUTIC APPLICATIONS | |
EP2280024A4 (en) | POLYPEPTIDE SPECIFICALLY COUPLED WITH PHOSPHATIDYLSERIN AND USE THEREOF | |
IL221723A0 (en) | Use of nogo - a binding molecules in the preparation of medicaments | |
EP1999261A4 (en) | USE OF PROTEIN S MELT FOR PROTEIN SOLUBILIZATION | |
EP2139318A4 (en) | FUSION PROTEINS WITH SPARKLE SPACERS AND THEIR USE | |
IL206334A0 (en) | Sarp-i fusion proteins and their use | |
EP1942911A4 (en) | THERAPEUTIC MOLECULES AND USES THEREOF | |
ZA200808656B (en) | Enzyme fusion proteins and their use | |
IL185575A0 (en) | Benzoxazocines and their therapeutic use | |
GB0614538D0 (en) | Therapeutic Compounds And Their Use | |
AU2005900650A0 (en) | Therapeutic Epitopes and Uses Thereof | |
GB0505908D0 (en) | Antibodies and their use in therapy | |
PT1833847E (pt) | Polipéptidos de fusão que contêm igf-1 e utilizações terapêuticas desses polipéptidos |